Last reviewed · How we verify
bivalirudin + clopidogrel + aspirin
This combination inhibits blood clotting through three complementary pathways: bivalirudin directly blocks thrombin, while clopidogrel and aspirin inhibit platelet aggregation.
This combination inhibits blood clotting through three complementary pathways: bivalirudin directly blocks thrombin, while clopidogrel and aspirin inhibit platelet aggregation. Used for Acute coronary syndrome undergoing percutaneous coronary intervention, Prevention of thrombotic complications during coronary angioplasty.
At a glance
| Generic name | bivalirudin + clopidogrel + aspirin |
|---|---|
| Also known as | Angiox Plavix Kardégic |
| Sponsor | Centre Hospitalier de PAU |
| Drug class | Anticoagulant + antiplatelet combination |
| Target | Thrombin (Factor IIa), P2Y12 receptor, cyclooxygenase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Bivalirudin is a direct thrombin inhibitor that prevents the conversion of fibrinogen to fibrin and platelet activation. Clopidogrel is a P2Y12 receptor antagonist that blocks platelet aggregation, and aspirin irreversibly inhibits cyclooxygenase to prevent thromboxane A2 synthesis. Together, this triple anticoagulant/antiplatelet regimen provides potent antithrombotic effects used during acute coronary interventions.
Approved indications
- Acute coronary syndrome undergoing percutaneous coronary intervention
- Prevention of thrombotic complications during coronary angioplasty
Common side effects
- Bleeding
- Thrombocytopenia
- Hypotension
- Dyspnea
Key clinical trials
- Downstream Versus Upstream Strategy for the Administration of P2Y12 Receptor Blockers (PHASE4)
- Anticoagulant Treatments and Percutaneous Coronary Angioplasty (PHASE4)
- Simplified Anti-Thrombotic Therapy for FFR (NA)
- Antithrombotic Effects of Ticagrelor Versus Clopidogrel (PHASE4)
- Comparison of Primary PCI vs. Post-thrombolysis PCI as Reperfusion Strategies in STEMI (PHASE4)
- Study of Tirofiban Administration in Patients With Aspirin and or Clopidogrel Resistance (PHASE4)
- A Registry To Evaluate Safety And Effectiveness Of Everolimus Drug Eluting Stent For Coronary Revascularization (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- bivalirudin + clopidogrel + aspirin CI brief — competitive landscape report
- bivalirudin + clopidogrel + aspirin updates RSS · CI watch RSS
- Centre Hospitalier de PAU portfolio CI